Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Free Cash Flow (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Free Cash Flow for 6 consecutive years, with -$1.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 82.9% to -$1.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$7.0 million, a 17.52% increase, with the full-year FY2024 number at -$7.5 million, up 30.4% from a year prior.
  • Free Cash Flow was -$1.9 million for Q3 2025 at Ensysce Biosciences, up from -$2.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$132312.0 in Q2 2021 to a low of -$6.7 million in Q3 2022.
  • A 5-year average of -$2.7 million and a median of -$2.7 million in 2025 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 3256.08% in 2022, then soared 66.3% in 2023.
  • Ensysce Biosciences' Free Cash Flow stood at -$3.8 million in 2021, then grew by 12.53% to -$3.3 million in 2022, then surged by 45.33% to -$1.8 million in 2023, then soared by 57.59% to -$764090.0 in 2024, then tumbled by 144.24% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Free Cash Flow are -$1.9 million (Q3 2025), -$2.7 million (Q2 2025), and -$1.7 million (Q1 2025).